Cyclopharm Ltd has released a press release.
USFDA Confirms Technegas Six Month Review Period
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Cyclopharm
- Technegas Enters Final Six Month USFDA Review Cycle
- Dividend/Distribution - CYC
- Cyclopharm Receives $1.64m R&D Refund
- Half Year 2022 Results
- Technegas Used In Multicenter COVID Study
Later from Cyclopharm
- Cyclopharm Confirms USFDA Scheduled Inspection Date
- Notification of buy-back - CYC
- Cyclopharm 2023 Half Year Accounts Update - Record Revenues
- USFDA Approval Process Update
- Half Year Accounts
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm